{"entity":{"id":"nct06111235","kind":"trial","name":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT","aka":[],"tldr":"A phase 3 trial of Cretostimogene grenadenorepvec in bladder & urothelial cancer, run by CG Oncology, Inc., active and no longer recruiting.","summary":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT is a phase 3 interventional study registered as NCT06111235 by CG Oncology, Inc., with 367 participants enrolled, started 2023-12-14 and due to reach its primary completion in 2026-11. Interventions recorded: Cretostimogene Grenadenorepvec.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06111235","url":"https://clinicaltrials.gov/study/NCT06111235"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["cretostimogene"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06111235","phase":"3","setting":"A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)","sponsor":"CG Oncology, Inc.","enrolled":367,"outcomes":[]},"route":"/trials/nct06111235/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"cretostimogene","kind":"drug","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/"}]}}